Treatments

*May 2020* The first lung cancer patient to be treated with a new type of immunotherapy involving the re-engineering of a patient's T cells, known as TCR T-cell therapy, took place at Winship Cancer Institute of Emory University (Winship) on May 7, 2020. The Winship patient is enrolled on a…

*May 2020* In this video, Dr. Carbone discusses acquired resistance to osimertinib in NSCLC.

*May 2020* The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile. Clinical benefit was observed with almonertinib (HS-10296) as treatment of patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed on previous EGFR tyrosine kinase inhibitors…

*June 2020* Webcast: Join the EGFR Registers and top lung cancer specialists discuss facts vs myths in lung cancer treatment. A must-see for EGFR lung cancer patients/survivors. Register and watch it here.

*June 2020* Webcast: Listen to top experts in lung cancer discuss and interpret the latest research from ASCO 2020 with EGFR Resisters co-founders, Ivy Elkins and Jill Feldman.  Very informative and a must-watch for lung cancer survivors. Register and watch it here.

*March 2020* A biopsy sample of tissue often is tested for specific genetic variations (also referred to as mutations) that may have a targeted inhibitor that represents a clear optimal treatment for that cancer. However, it may not be possible to get enough tissue from the tumor to do these studies.…

*March 2020* Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC); however, ongoing research efforts are looking to build upon the benefits with combination strategies and prevent acquired resistance to treatment, explained David P. Carbone, MD, PhD. “It's an incredibly exciting…

*March 2020* Targeted sequencing of patients with acquired resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) for EGFR T790M-mutant non-small cell lung cancer (NSCLC) revealed that resistance is associated with diverse pathways. The retrospective study looked at the genomic landscape of 113 specimens taken from patients with EGFR-mutant disease who…

*February 2020* Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s Comprehensive Cancer Center. His many decades of research in MET and other oncogenic drivers has helped further lung cancer research and patient…

*March 2020* The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a Johnson & Johnson Company. NJ-6372 is an investigational treatment for metastatic non-small cell lung cancer (mNSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. It has been approved…